Please correct me if I am mistaken here bio........"Please allow me to first start by clarifying that the Company has stated publicly, on several occasions, that we expect to share the first readouts from the first P2a study mid-year. After evaluating the downward trend in the stock market across the biotech sector, since the beginning of the year, and given that the summer months are a quiet time amongst institutional investors, we felt it best for the Company to share those readouts in the early part of the Fall. Late Q3 and Q4 are typically a very active time in the investment community and can provide a good platform for a company to share results rather than in a market under tremendous pressure leading into the summer holiday."
The way I read this, RXI has readouts of first p2 but elects to disclose at a more opportune time. If so, then the announcement of the start of a third p2 trials was based on favorable readouts perhaps?
Also, it indicated that they may be sharing same at any time now. Not attempting to read too much into anything here but is does seem to add up...........just a thought this morning.........GLTA
everyone knows q3 is a bad quarter. i just dont understand how they could show their face at the wainwright conference in mid september and not update the phase 2 study if they had results. why even attend? so the price can get shorted below $2 a share when they dont announce anything meaningful. we will wait and see, but it is what it is.
I think you are right. They know the results are good, because the CEO even mentioned that he was pleased with the pictures he saw even though they were double-blinded. Also the initiation of the 3rd phase 2 trial is good because it deals with hyypertrophic scars in other areas of the body other than the abdomen area. So you are correct rmsacc things are looking up.